Identification and functional characterization of a highly polymorphic region in the human TRAIL promoter in multiple sclerosis

Research output: Contribution to journal › Research article › Contributed › peer-review

Contributors

  • Alexandra Weber - , Charité – Universitätsmedizin Berlin (Author)
  • Klaus Peter Wandinger - , Charité – Universitätsmedizin Berlin (Author)
  • Wolf Mueller - , Charité – Universitätsmedizin Berlin (Author)
  • Orhan Aktas - , Charité – Universitätsmedizin Berlin (Author)
  • Oliver Wengert - , Charité – Universitätsmedizin Berlin (Author)
  • Eva Grundström - , Charité – Universitätsmedizin Berlin (Author)
  • Stefan Ehrlich - , Charité – Universitätsmedizin Berlin (Author)
  • Christine Windemuth - , University of Bonn (Author)
  • Tanja Kuhlmann - , McGill University Health Centre (Author)
  • Thomas Wienker - , University of Bonn (Author)
  • Wolfgang Brück - , Charité – Universitätsmedizin Berlin, University of Göttingen (Author)
  • Frauke Zipp - , Charité – Universitätsmedizin Berlin (Author)

Abstract

TNF-related apoptosis-inducing ligand (TRAIL) is not only involved in cell death but also in other immunoregulatory mechanisms. So far, the regulation of the TRAIL pathway in physiologic and pathologic conditions remains unclear. Due to the implication in brain damage and the elevated expression in peripheral immune cells of patients with multiple sclerosis (MS), an autoimmune disease of the central nervous system, TRAIL might play a central role in the pathology of this disease. Here, we have identified a highly polymorphic region in the TRAIL promoter. Using single-strand conformation polymorphism analysis, we found four single nucleotide polymorphisms (SNPs) within 111 base pairs. One of these SNPs is located in a binding site for the transcription factor AP-1. However, the RNA and protein expression of TRAIL revealed no obvious differences in relation to the genotypes. Furthermore, investigating samples from both MS patients and healthy controls we could not detect any association of these newly described polymorphisms to the clinical disease pattern. Thus, the TRAIL promoter contains a highly polymorphic area which has, however, no impact on molecule expression, and is neither directly related to increased risk of developing MS nor associated with a certain course of this heterogeneous disease in our population.

Details

Original languageEnglish
Pages (from-to)195-201
Number of pages7
JournalJournal of neuroimmunology
Volume149
Issue number1-2
Publication statusPublished - Apr 2004
Peer-reviewedYes
Externally publishedYes

External IDs

PubMed 15020080
ORCID /0000-0003-2132-4445/work/202353718

Keywords

Keywords

  • Central nervous system, CNS, EDSS, Expanded Disability Status Scale, HLA, Human leukocyte antigen, Immunogenetics, MS, Multiple sclerosis, PCR, Polymerase chain reaction, RFLP, Single nucleotide polymorphisms, TRAIL